What if off-the-shelf CAR-T wins approval at a tenth of the cost?
Clean chain: an approved allogeneic off-the-shelf CAR-T at one-tenth the cost disrupts autologous incumbents and CDMO economics — long allogeneic platforms (Allogene-type), short autologous-cell makers and the contract-manufacturing build-out thesis. No clean macro analogue; it is a classic cost-curve disruption within cell therapy. Immaterial to macro — the small risk-on cascade is noise; trade the allogeneic-vs-autologous pair.
Every number ships with its receipt — the odds, the range, the precedents, and a public grade at Reality Check. The statistical machinery that produces it is proprietary.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (electric blue) over time vs the market's (Polymarket, amber), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. Loading the probability audit trail…
What it would mean
If this plays out, it is a mixed shock. Allogeneic off-the-shelf CAR-T wins approval at one-tenth the cost, disrupting autologous-cell incumbents and CDMO economics. The trigger decomposes into signed root‑shocks — Risk appetite ▲ — which propagate through our causal graph to the markets below.